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Abstract
Fibrinogen (Fg) is one of the biomarkers of inflammation and a high risk factor for many 
cardiovascular and cerebrovascular diseases. Elevated levels of Fg (hyperfibrinogenemia, 
HFg) are also associated with traumatic brain injury (TBI). HFg in blood alters vascular 
reactivity and compromises integrity of endothelial cell layer that ultimately can result in 
extravasation of Fg and other plasma proteins. Proteins deposited in extravascular space 
may form plaques which can lead to neurodegeneration. Among these plasma proteins 
are amyloid beta (Aβ) and/or cellular prion protein (PrPC) that can form degradation 
resistant complexes with Fg and are known to be involved in memory impairment. The 
purpose of this chapter is to propose and discuss some possible mechanisms involved in 
HFg-mediated cerebrovascular dysfunction leading to neuronal degeneration during TBI.
Keywords: astrocytes, fibrinogen deposition, neuroinflammation, neurodegeneration, 
neurovascular unit
1. Introduction
Traumatic brain injury (TBI) is the devastating cause of death and disability worldwide, for 
which no effective treatment exists other than supportive care [1]. It is a heterogeneous disease 
that is classically classified as mild, moderate, and severe TBI according to clinical severity 
using the Glasgow coma scale (GCS) for evaluation [2]. According to epidemiological data 
falls are the leading cause of TBI, followed by vehicle accidents and physical assaults includ-
ing sports-related head traumas along with blast injuries that mainly occur in war zones. 
Pathoanatomic classification of TBI includes penetrating (open) or closed (blunt) head injuries, 
hemorrhages (epidural, subdural, subarachnoid, intraparenchymal, intraventricular) as well as 
focal and diffuse patterns of lesions. Classification of TBI by outcome includes categories such 
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as death, vegetative state, disability (severe or moderate) and good recovery. Etiologically TBI 
is subdivided into “primary” and “secondary” injury based on their triggering mechanisms. 
Thus, while “primary” injury occurs immediately after a direct physical impact of damaging 
force, the “secondary” injury is a result of adverse effects of responses in the parenchymal tis-
sue developing due to the “primary” injury. Defining TBI classification is very important for 
further diagnostic, treatment, clinical management, and prevention and prediction of outcome 
in patients with TBI [3].
TBI is associated with systemic inflammation [4, 5] that includes elevation of plasma content 
of fibrinogen (Fg, called hyperfibrinogenemia, HFg). According to clinical data blood level 
of Fg is elevated after mild-to-moderate TBI (when vascular ruptures are minimal or nonex-
istent) [6]. It is known that formation of Fg-containing protein complexes is associated with 
memory reduction emphasizing role of this inflammatory protein. Therefore, in this chapter 
we propose and discuss possible mechanisms involved in alterations of neuronal function 
associated with systemic inflammation particularly with HFg during TBI. Since at elevated 
levels Fg affects vasculature and only then it is involved in vasculo-astrocyte uncoupling [7], 
the main emphases are given to neuronal degeneration or dysfunction that occurs due to 
changes in cerebrovascular properties.
2. Traumatic brain injury and blood-brain barrier
The harmful effects of TBI occur during primary injury and secondary complications. Primary 
damage is induced by a mechanical force that causes compression and physical damage of 
brain parenchyma that leads to changes in neurovascular unit (NVU) [8, 9]. The second-
ary complications can occur days or months or years after the initial insult due to further 
development of chronic inflammation, vascular impairment, chronic ischemia or progressive 
neurodegeneration [9, 10]. They may involve blood-brain barrier (BBB) impairment, cogni-
tive decline, and memory deficiency [11]. Disruption of BBB has often been documented in 
patients with TBI [12], but the role of vascular pathology and its consequences in neurological 
dysfunction has only recently become a sphere of high interest.
BBB is the regulated interface between the peripheral circulation and the central nervous sys-
tem (CNS). BBB is constituted by the cerebrovascular endothelial cells (ECs) and vascular 
smooth muscle cells, and together with astrocytes, pericytes, neurons, and associated extra-
cellular matrix proteins represents a NVU [13]. Majority of CNS diseases are associated with 
mechanical and functional disruption in NVU. The changes and regulation of ion balance 
and homeostasis, oxygen and nutrition supply, transport of hormones and neurotransmitters 
depend on normal function of cerebral vessels and blood flow properties. Therefore, because 
of events initiated in the vasculature as a result of vascular dysfunction, alterations in blood 
flow and/or changes in blood component properties, which prompt or exacerbate neuronal 
dysfunction/degeneration, the term “vasculo-neuronal” dysfunction seems more appropriate 
to emphasize the source of destructive effect in CNS [10].
Studies have shown that increased BBB permeability is involved in initiation of pathological 
changes in the neuro-vascular network leading to neuronal dysfunction and degeneration. 
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BBB breakdown in patients with TBI usually confirmed with brain imaging results, and it is 
suggested to use it as a biomarker in the clinical studies and in drug trials.
The disruption of integrity of vascular walls caused by injury allows proteins such as throm-
bin, albumin, and/or Fg to enter CNS parenchyma. These proteins have the ability to activate 
astrocytes and microglia, which are the integral components of the NVU. These effects can be 
the cause of an increase in synthesis of pro-inflammatory cytokines, including tumor necrosis 
factor (TNF-α), interlukin-1 (IL-1), interlukin-6 (IL-6), and others [14].
3. Inflammatory markers during TBI
The inflammatory markers can be defined as pro- and anti-inflammatory. The most com-
monly observed pro-inflammatory cytokines such as TNF-a, IL-1, IL-6 are elevated during 
TBI [14]. Interestingly, levels of an anti-inflammatory interlukin-10 (IL-10) are also elevated 
during TBI [15].
TBI-induced inflammation activates acute-phase responses. One of the most known acute-
phase proteins is C reactive protein (CRP), which perceptibly increases during inflammation 
and rapidly decreases after inflammation subsides [16]. On the other hand, blood level of 
another acute-phase protein—Fg increases slowly and returns to its normal level about 21 days 
post-inflammatory stimuli [16]. Since Fg itself results in inflammatory responses [17–26], 
besides being an inflammatory marker, it is considered as a pro-inflammatory protein.
In brain tissue, TNF-α, a well-known pro-inflammatory cytokine, is produced by microglia, 
astrocytes, endothelial cells, and neurons. The effects of TNF-α are associated with apoptotic/
necrotic cell death induction [27]. TNF-α expression takes place shortly after neuronal injury 
and it is actively involved in process of neutrophil and monocyte recruitment to the site of 
the damage. The appearance of TNF-α varies from 1 to 24 h following the trauma (the peak 
is considered at 4–12 h following initial insult). Some scientists consider TNF-α as a marker 
of severe TBI [28]. There are data indicating a significant association of TNF-α with cognitive 
impairment during TBI [29]. However, it is known that in addition to induction of apoptotic/
necrotic cell death, TNF-α is also involved in stimulation of cell growth and differentiation. 
Therefore, the role of TNF-α during TBI may still remain unclear since it has been shown to 
possess both neurotoxic and neuroprotective effects [27].
The main function of IL-1 is regulation and release of other cytokines. It is expressed in mul-
tiple cell types in the brain tissue. Expression of IL-1 is mostly associated with acute TBI [30]. 
There is a discrepancy in literature regarding the IL-1 detection in serum and cerebrospinal 
fluid (CSF) during TBI. One of the most reported isoforms of IL-1 family in TBI patients is 
IL-1β. It is highly involved in release of prostaglandins, apoptosis, leukocyte adhesion to ECs, 
BBB disruption, and edema formation. The use of IL-1 receptor antagonist, which improves 
cellular and behavioral outcomes emphasizes the basic pro-inflammatory and neurotoxic 
effect of IL-1 during TBI [30].
While some consider IL-6 a highly sensitive, but not specific biomarker for neurotrauma [28], 
others claim that it is not exclusively expressed in response of head trauma and predominantly 
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 indicates state of BBB integrity [31]. IL-6 is expressed by astrocytes, glial cells and neurons. 
Normally it is not detectable in serum and plasma but under pathological conditions level 
of IL-6 increases and points to mainly axonal injury [28]. Drastically increased levels of IL-6 
are observed in CSF during severe TBI that reaches its maximum levels in about 3 to 6 days 
after the initial insult. The involvement of IL-6 in cognitive impairment during TBI in mice 
is shown [32]. However, although IL-6 can be a strong marker of TBI-induced inflammation, 
use of IL-6 as a possible therapeutic target is limited as it cannot readily cross the vascular 
wall [30].
Interlukin-8 (IL-8) belongs to chemokines, a special class of small cytokines. It is secreted by 
endothelial cells, glial cells, neurons, macrophages, lymphocytes and neutrophils [28]. IL-8 
induces chemotaxis and neutrophil phagocytosis and causes its attraction to the site of dam-
age and inflammation. Generally the persistence of the activated leukocytes in brain from 1 
to 4 weeks after injury is neurotoxic, and exacerbates the ongoing neuronal damage [28]. The 
level of IL-8 in CSF is greater than in plasma or serum during head injuries.
The most well-known anti-inflammatory cytokine IL-10 serves as an inhibitor of pro-inflam-
matory mediators and regulates the cytokines. It is suggested that IL-10 reduces the neuro-
inflammation during TBI. It increases 24 hours after severe initial insult and coincides with 
decrease in TNF-α levels. In rat model of TBI, treatment with IL-10 results in reduction of 
IL-1β and TNF-α levels in brain tissue and improves neurological recovery [28].
Activation of transcription factor, nuclear factor kappa B (NF-kB) that is also considered as 
an inflammatory marker, has been shown to play a key role in inflammatory response, neu-
ronal survival and signaling [33]. First appearance of NF-kB occurs in axons shortly after 
trauma (1–2 h), and then in neurons (24 h) and lasts up to 1 week. Later (24 hours after initial 
insult), activated NF-kB is detected in microglia, macrophages, and astrocytes in cortexes [33]. 
Activated NF-kB is also detected in ECs, as early as 1 h after initial insult, and persists there 
for up to 1 year [33]. Hence, it can be suggested that NF-kB activation plays a role in long-term 
inflammatory processes during TBI.
4. Fibrinogen (Fg)
One of the inflammatory mediators which is released after TBI-induced inflammation is Fg. 
It is a high molecular weight (~ 340 kD) plasma adhesion glycoprotein, that is primarily syn-
thesized in hepatocytes. Inflammatory cytokines such as IL-1 and IL-6 are involved in Fg syn-
thesis and stimulation of its synthesis, while increased plasma level of albumin suppresses it. 
Overexpression of these cytokines, that occurs during inflammation leads to HFg [34], which is 
a biomarker of inflammation and high risk factor for many cerebrovascular disorders [35–38]. 
Normally Fg concentration in blood is around 2 mg/ml. Higher content of Fg in blood is consid-
ered as a state of inflammation [39, 40] and it can be a cause of inflammatory responses [41]. It 
was shown that at high (≥4 mg/ml) levels Fg increases arteriolar constriction [18], regulates pro-
duction of endothelin-1 (ET-1) [19], enhances vascular layer permeability [21] to proteins, and 
can itself leak through the EC layer [20]. Since Fg is synthesized in hepatocytes and circulates 
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in blood, it may appear in extravascular space only after crossing the vascular wall. In brain, 
it may occur only if BBB is dysfunctional. Gradual deposition of Fg accelerates neurovascular 
damage and promotes neuroinflammation [42, 43].
Some clinical studies indicate that TBI is accompanied by hypo-fibrinogenemia, abnormally 
decreased blood level of Fg [44]. During severe brain injury that results in rapture of brain ves-
sels and hemorrhage, blood cells and plasma components, including Fg come out of vessels. 
Particularly in the first 72 hours, the hemorrhage is an obvious cause of hypo-fibrinogenemia 
[44, 45]. In addition, activation of fibrinolytic system exacerbates hypo-fibrinogenemia [46]. 
However, 2 weeks after severe trauma and/or mild-to-moderate brain injury (when vascular 
ruptures are minimal or nonexistent), blood content of Fg increases [6, 47]. HFg can be notice-
able in patients even 12 hours after initial insult [45]. Therefore, Fg crossing of vessel walls 
and its subsequent deposition in extravascular space, after the initial injury, can be a result of 
systemic or local inflammation.
5. Inflammation / vascular permeability / edema
Inflammation is a complex of different biological responses of vascular tissue to harmful stim-
uli. The actions of various inflammatory mediators cause significant vascular changes such as 
increased permeability (hyper-permeability), vasodilation, and worsening of hemorheology 
[48]. Majority of vascular diseases that are associated with inflammation include stroke [49], 
myocardial infarction [50], hypertension [51, 52], diabetes [53, 54], atherosclerosis [55], and 
TBI [4, 5, 12]. Inflammation is a key contributor to many vascular diseases and plays a major 
role in autoimmune diseases [56], allergic reactions [57], and cancer [58]. Neuroinflammation 
is one of the crucial stage of injury after brain trauma [28].
Inflammatory processes may induce endothelial dysfunction and vascular remodeling [51, 59]. 
The normal endothelium forms a stable anti-inflammatory interface between circulating blood 
components and cells within tissues. The endothelium builds a barrier, which along with its 
associated structures such as basement membrane and/or glycocalyx maintain the relatively 
constant plasma volume and venous return, and prevent tissue edema [60]. Maintaining tis-
sue homeostasis and contributing the functions of the vessel wall by establishing communica-
tions between blood and adjacent tissue are the two pivotal functions of vascular endothelium, 
which functions as a barrier and a permeable filter at the same time [61].
Increase in vascular permeability is one of the indications of inflammation. In result of hyper-
permeability, blood plasma substances and proteins move out of the blood stream and deposit 
in subendothelial matrix (SEM) and interstitium and may cause edema [41, 62]. This phenom-
ena can occur during mainly an early stages of acute inflammation [63].
One of the most dangerous secondary consequences of TBI with significant morbidity and 
mortality is cerebral edema. It is an abnormal accumulation of fluid within the brain paren-
chyma and is classified as vasogenic and cytotoxic [31]. Vasogenic edema is defined as fluid 
originating from blood vessels that accumulates around cells. Cytotoxic edema is defined 
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as fluid accumulating within cells as a result of injury. The most common cytotoxic edema 
occurs in cerebral ischemia. Heretofore, the edema specific to TBI has generally been consid-
ered to be of vasogenic origin, secondary to traumatic opening of the BBB. However, lately 
clinical studies showed the significant role of cytotoxic edema [31]. It is possible that both 
forms of edema can coexist. To define the type of edema (mostly by imaging technique) may 
be a decisive moment, as effective treatment will clearly depend on the major type of edema 
contributing to the brain swelling process.
6. Transvascular transport pathways
There are two major transport pathways for blood plasma components to pass through the 
endothelial barrier: transcellular and paracellular [62, 64, 65]. Paracellular pathway takes 
place when plasma components move between the ECs. It involves alterations in junction 
proteins and their interbinding forces [62]. It is implied that low molecular weight molecules 
take this pathway as oppose to transcellular transport of high molecular weight molecules 
such as proteins, which occurs mainly through the ECs and involves formation of functional 
caveolae (and/or fenestrae, and/or transendothelial channels [64]) and its motility [66]. Thus, 
movement of proteins across the vascular wall via transcellular transport pathway can be 
defined as caveolar transcytosis [67]. At elevated levels Fg can enhance caveolar transcytosis 
[68, 69]. The net transport of blood plasma substances in microcirculation is governed by the 
combination and the functional balance of transcellular and paracellular pathways.
Head injury-induced inflammation leads to an increased blood content of Fg [6, 47]. At ele-
vated levels, Fg increases vascular permeability to other proteins and itself crosses the vas-
cular wall [20, 47]. During majority of cardiovascular and cerebrovascular inflammatory 
diseases, increased levels and/or activity of the plasminogen system have not been observed. 
For example, activity of tissue plasminogen activator (tPA) is diminished in brains of patients 
with Alzheimer’s disease (AD), mouse models of the disease [68], and during various inflam-
matory traumas [46]. Thus, an increased leakage of Fg, in the context of decreased or unaltered 
activity of the plasminogen system, leads to an enhanced deposition of Fg in extravascular 
space in pathologies such as TBI and AD. There, immobilized Fg can form different protein 
complexes [47, 70]. Furthermore, immobilized Fg is converted to fibrin by thrombin. Since 
protein fibrinolytic system can no longer counterbalance excess formation of fibrin, enhanced 
deposition of fibrin exacerbates neurovascular damage and neuroinflammation [42, 71].
7. Fg-containing complexes
After extravasation Fg deposits into parenchyma and makes complexes with other proteins. 
The most known is Fg amyloid beta (Aβ) protein complex, called amyloid plaque [72], which 
is a hallmark of AD and it is associated with loss of memory [73]. The defects in Aβ and its pre-
cursor protein (APP) are considered a cause of AD and dementia. The neurotoxic Aβ peptide 
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(oligomers of Aβ) is derived from the APP and it is considered as a major constituent of the 
plaques. After deposition in SEM, Fg becomes readily available for binding to Aβ oligomers 
and even APP. The appearance of Fg-Aβ and/or Fg-APP complexes can be a result of vascular 
hyper-permeability leading to transcytosis of Fg to SEM [74]. It has been shown that binding 
of Aβ to Fg leads to its oligomerization [70], and Fg-Aβ complex is highly resistant to degra-
dation [75]. Similarly, there is a strong evidence that Fg, which is found immobilized in extra-
vascular space, besides being associated with Aβ, can also be associated with other proteins, 
such as collagen and cellular prion protein (PrPC). Alteration of collagen content in SEM is one 
of the indications of vascular remodeling. Increased collagen level in cerebral microvessels 
during AD has been shown [76]. It was shown that collagen can serve as a substrate for Fg-Aβ 
complex deposition in SEM [74]. The present results indicate an increased formation of col-
lagen along with increased expression of Aβ and enhanced deposition of Fg and Aβ. Data sug-
gest that during inflammation, increased cerebrovascular permeability leads to an enhanced 
deposition of Fg on SEM collagen through formation of Fg-Aβ-collagen complex, which was 
found to be correlated with reduction of short-term memory [74].
Some studies indicate that Aβ has a limited effect on memory and point to a greater role of PrPC 
[77, 78]. It was found that Fg interacts with non-digested scrapie prion protein [79]. Results 
of our studies also point to the role of PrPC in memory impairment during HFg [80] and TBI 
[47]. Therefore, formation of Fg-Aβ and/or Fg-PrPC complexes may indicate a mechanism for 
memory reduction seen in diseases such as TBI, associated with inflammatory cerebrovascu-
lar impairment. As a result, these findings highlight a new role of Fg during inflammation-
induced impairment of vascular wall properties and thus, vasculo-neuronal unit dysfunction.
8. Oxidative damage and neurodegeneration
TBI-induced inflammation and increased cerebrovascular permeability lead to translocation 
of Fg from vessels to the extravascular space, and its deposition most likely in the vasculo-
astrocyte endfeet interface, which may cause astrocyte activation and vascular and astrocyte 
physical and functional uncoupling [7]. This may result in neuronal degeneration and possi-
ble decline in short-term memory [7]. Possible mechanism for this vasculo-neuronal dysfunc-
tion can be an activation of astrocytes leading to tyrosine kinase receptor B (TrkB)-mediated 
enhanced production of reactive oxygen species (ROS) and nitric oxide (NO), which result in 
neuronal degeneration [81].
Oxidative damage and free radical formation remains one of the important contributors to 
the pathophysiology of TBI. Generation of ROS causes damage of neuronal membranes, 
which results in subsequent disruption in ion balance and homeostasis, mitochondrial func-
tion failure, and microvascular damage [82]. ROS such as hydrogen peroxide, hydroxyl radi-
cal, superoxide onion, peroxyl radical (hydroperoxyl), singlet oxygen, and NO are the highly 
reactive molecules produced during monocyte migration. They contribute to BBB impairment 
and inflammation in brain after trauma [83]. The cascade of ROS production begins immedi-
ately within the first hours after initial insult and lasts for several days [82]. The  amplification 
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of neurodegeneration can be caused by neuronal NO production. This process is highly 
dependent on TrkB receptor regulation on astrocytes. It was shown that depletion of TrkB 
protected experimental animals from neurodegeneration [81]. Fg prompts rapid microglial 
responses toward the cerebrovascular system and axonal damage during neuroinflammation 
[84]. Extravasation of Fg and deposited fibrin correlate with axonal damage and cause ROS 
formation in microglia [84]. In vitro, it was shown that astrocytes remove Fg coating from the 
growth surface that results in their activation and disappearance [85]. Reduction in astrocyte 
population may be due to their death. Fibrin activates astrocytes by transforming the growth 
factor beta receptor pathway and promotes astrocyte scar formation after vascular rupture 
during severe TBI [71]. These findings suggest that there is a strong interactive association 
between Fg/fibrin and astrocytes [7, 71].
9. Role of Fg in loss of memory during TBI
Cognitive impairment and particularly memory deficiency is a result of neurodegeneration 
and is one of the devastating problems of people with neurotrauma [86]. The role and con-
tribution of Fg in development of AD is known [70, 72, 75]. Strong association of Fg-Aβ 
complex formation is linked to severity of AD [70, 72, 75]. Thus, deposition of Fg in extravas-
cular space and formation of Fg-Aβ complexes can be a major indicator for memory reduc-
tion during TBI. Similarly, possible formation of Fg-PrPC complexes may result in memory 
impairment.
The Prion diseases, one of the forms of encephalopathies, are the group of progressive neuro-
degenerative conditions with memory impairment. The role of PrPC in cognitive dysfunction 
has been shown [77, 78]. Increased formation of Fg-PrPC complex in mice during TBI was 
accompanied by reduction in short-term memory [47]. Combined, these results indicate that 
PrPC alone as well as its possible association with Fg can have a role in memory reduction 
during inflammatory cerebrovascular diseases.
10. Conclusion
Thus, TBI-induced inflammation besides directly affecting neurons, leads to vasculo-neuronal 
dysfunction resulting in Fg deposition in extravascular space and formation of Fg-containing 
protein complexes between the vessels and astrocyte endfeet. Enhanced cerebrovascular per-
meability can be a first and the most important step in the process leading to alterations in 
cognitive function. Thus, at elevated levels, Fg can play a significant role in vascular cognitive 
impairment and dementia (VCID) (Figure 1). There is a great attention to the problems related 
to VCID in the past few years. Presented review indicates that Fg has a significant role in 
vascular permeability, neuroinflammation and cognitive impairment. Therefore, as a possible 
diagnostic or outcome predicting approach, it seems important to carefully monitor plasma 
levels of Fg during TBI. Simultaneously targeting multiple mechanistic components of an 
altered vasculo-neuronal interaction after head injury, such as blood level of Fg and PrPC may 
be an effective therapeutic approach to ameliorate TBI-induced neurovascular inflammation.
Traumatic Brain Injury - Pathobiology, Advanced Diagnostics and Acute Management112
Author details
Nino Muradashvili, Suresh C. Tyagi and David Lominadze*
*Address all correspondence to: david.lominadze@louisville.edu
Department of Physiology, University of Louisville, School of Medicine, Louisville, KY, USA
References
[1] Brody D, Mac Donald C, Kessens C, Yuede C, Parsadanian M, Spinner M, Kim E, 
Schwetye K, Holtzman D, Bayly P. Electromagnetic controlled cortical impact device for pre-
cise, graded experimental traumatic brain injury. Journal of Neurotrauma. 2007;24:657-673
[2] Teasdale G, Jennett B. Assessment of coma and impaired consciousness: A practical 
scale. The Lancet. 1974;304:81-84
[3] Saatman KE, Duhaime A-C, Bullock R, Maas AIR, Valadka A, Manley GT. Classification 
of traumatic brain injury for targeted therapies. Journal of Neurotrauma. 2008;25:719-738
[4] Cederberg D, Siesjö P. What has inflammation to do with traumatic brain injury? Child's 
Nervous System. 2010;26:221-226
Figure 1. Possible mechanism of traumatic brain injury (TBI)-induced cognitive impairment. TBI causes inflammation 
leading to an increase in inflammatory markers including C reactive protein (CRP), interleukins 1 and 6 (IL-1 and IL-6, 
respectively) and fibrinogen (Fg). The latter exacerbates TBI-induced cerebrovascular permeability resulting in enhanced 
deposition of Fg in vasculo-astrocyte endfeet interface, and formation of Fg-containing complexes with proteins Aβ and 
PrPC, which are known to be involved in cognitive decline. In addition, activation of astrocytes causing upregulation of 
tyrosine kinase receptor B (TrkB) results in formation of reactive oxygen species leading to neurodegeneration.
Role of Fibrinogen in Vascular Cognitive Impairment in Traumatic Brain Injury
http://dx.doi.org/10.5772/intechopen.72610
113
[5] Ziebell J, Morganti-Kossmann M. Involvement of pro- and anti-inflammatory cytokines 
and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics. 
2010;7:22-30
[6] Mansoor O, Cayol M, Gachon P, Boirie Y, Schoeffler P, Obled C, Beaufrère B. Albumin 
and fibrinogen syntheses increase while muscle protein synthesis decreases in head-
injured patients. American Journal of Physiology. Endocrinology and Metabolism. 1997; 
273:E898-E902
[7] Muradashvili N, Tyagi SC, Lominadze D. Localization of fibrinogen in the vasculo-
astrocyte interface after cortical contusion injury in mice. Brain Sciences. 2017;7:77
[8] Moppett I. Traumatic brain injury: Assessment, resuscitation and early management. 
British Journal of Anaesthesia. 2007;99:18-31
[9] Walker PA, Shah SK, Harting MT, Cox CS. Progenitor cell therapies for traumatic 
brain injury: Barriers and opportunities in translation. Disease Models & Mechanisms. 
2009;2:23-38
[10] Muradashvili N, Lominadz D. Role of fibrinogen in cerebrovascular dysfunction after 
traumatic brain injury. Brain Injury. 2013;27:1508-1515
[11] Rostami R, Salamati P, Yarandi KK, Khoshnevisan A, Saadat S, Kamali ZS, Ghiasi S, 
Zaryabi A, Ghazi Mir Saeid SS, Arjipour M, Rezaee-Zavareh MS, Rahimi-Movaghar V. 
Effects of neurofeedback on the short-term memory and continuous attention of patients 
with moderate traumatic brain injury: A preliminary randomized controlled clinical 
trial. Chinese Journal of Traumatology. 2017;20:278-282
[12] Shlosberg D, Benifla M, Kaufer D, Friedman A. Blood-brain barrier breakdown as a 
therapeutic target in traumatic brain injury. Nature Reviews. Neurology. 2010;6:393-403
[13] Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and dis-
ease. Pharmacological Reviews. 2005;57:173-185
[14] Chodobski A, Zink BJ, Szmydynger-Chodobska J. Blood-brain barrier pathophysiology 
in traumatic brain injury. Translational Stroke Research. 2011;2:492-516
[15] Garcia JM, Stillings SA, Leclerc JL, Phillips H, Edwards NJ, Robicsek SA, Hoh BL, 
Blackburn S, Doré S. Role of Interleukin-10 in acute brain injuries. Frontiers in Neurology. 
2017;8:244
[16] Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflamma-
tion. The New England Journal of Medicine. 1999;340:448-454
[17] Muradashvili N, Qipshidze N, Munjal C, Givvimani S, Benton RL, Roberts AM, Tyagi SC, 
Lominadze D. Fibrinogen-induced increased pial venular permeability in mice. Journal 
of Cerebral Blood Flow and Metabolism. 2012;32:150-163
[18] Lominadze D, Tsakadze N, Sen U, Falcone JC, D'Souza SE. Fibrinogen- and fragment 
D-induced vascular constriction. American Journal of Physiology. 2005;288:H1257-H1264
Traumatic Brain Injury - Pathobiology, Advanced Diagnostics and Acute Management114
[19] Sen U, Tyagi N, Patibandla PK, Dean WL, Tyagi SC, Roberts AM, Lominadze D. 
Fibrinogen-induced endothelin-1 production from endothelial cells. American Journal 
of Physiology. Cell Physiology. 2009;296:C840-C847
[20] Tyagi N, Roberts AM, Dean WL, Tyagi SC, Lominadze D. Fibrinogen induces endothe-
lial cell permeability. Molecular and Cellular Biochemistry. 2008;307:13-22
[21] Patibandla PK, Tyagi N, Dean WL, Tyagi SC, Roberts AM, Lominadze D. Fibrinogen 
induces alterations of endothelial cell tight junction proteins. Journal of Cellular 
Physiology. 2009;221:195-203
[22] Muradashvili N, Tyagi N, Tyagi R, Munjal C, Lominadze D. Fibrinogen alters mouse 
brain endothelial cell layer integrity affecting vascular endothelial cadherin. Biochemical 
and Biophysical Research Communications. 2011;413:509-514
[23] Koenig W. Fibrin(ogen) in cardiovascular disease: An update. Thrombosis and Haemo-
stasis. 2003;89:601-609
[24] Patibandla PK, Tyagi N, Tyagi SC, Dean WL, Roberts AM, Lominadze D. An elevated 
fibrinogen increases matrix metalloproteinases activity in cardiac microvascular endo-
thelial cells. Experimental Biology. 2009;23:592, 10
[25] Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. 
Seminars In Immunopathology. 2012;34:43-62
[26] Vitorino de Almeida V, Silva-Herdade A, Calado A, Rosário H, Saldanha C. Fibrinogen 
modulates leukocyte recruitment in vivo during the acute inflammatory response. 
Clinical Hemorheology and Microcirculation. 2015;59:97-106
[27] Longhi L, Perego C, Ortolano F, Aresi S, Fumagalli S, Zanier ER, Stocchetti N, Simoni 
M-GD. Tumor necrosis factor in traumatic brain injury: Effects of genetic deletion of p55 
or p75 receptor. Journal of Cerebral Blood Flow and Metabolism. 2013;33:1182-1189
[28] Werhane ML, Evangelista ND, Clark AL, Sorg SF, Bangen KJ, Tran M, Schiehser DM, 
Delano-Wood L. Pathological vascular and inflammatory biomarkers of acute- and 
chronic-phase traumatic brain injury. Concussion. 2017;2:CNC30
[29] Baratz R, Tweedie D, Wang J-Y, Rubovitch V, Luo W, Hoffer BJ, Greig NH, Pick CG. 
Transiently lowering tumor necrosis factor-α synthesis ameliorates neuronal cell loss 
and cognitive impairments induced by minimal traumatic brain injury in mice. Journal 
of Neuroinflammation. 2015;12:45
[30] Woodcock T, Morganti-Kossmann C. The role of markers of inflammation in traumatic 
brain injury. Frontiers in Neurology. 2013;4:18
[31] Winkler EA, Minter D, Yue JK, Manley GT. Cerebral Edema in traumatic brain injury. 
Neurosurgery Clinics of North America. 2016;27:473-488
[32] Yang SH, Gustafson J, Gangidine M, Stepien D, Schuster R, Pritts TA, Goodman MD, 
Remick DG, Lentsch AB. A murine model of mild traumatic brain injury exhibiting cog-
nitive and motor deficits. Journal of Surgical Research. 2013;184:981-988
Role of Fibrinogen in Vascular Cognitive Impairment in Traumatic Brain Injury
http://dx.doi.org/10.5772/intechopen.72610
115
[33] Nonaka M, Chen X-H, Pierce JES, Leoni MJ, McIntosh TK, Wolf JA, Smith DH. Prolonged 
activation of NF-κB following traumatic brain injury in rats. Journal of Neurotrauma. 
1999;16:1023-1034
[34] Nakamura A, Kohsaka T, Johns EJ. Neuro-regulation of interleukin-6 gene expression 
in the spontaneously hypertensive rat kidney. Journal of Hypertension. 1996;14:839-845
[35] del Zoppo GJ, Levy DE, Wasiewski WW, Pancioli AM, Demchuk AM, Trammel J, 
Demaerschalk BM, Kaste M, Albers GW and Ringelstein EB. Hyperfibrinogenemia and 
functional outcome from acute ischemic stroke. Stroke 2009;40:1687-1691
[36] Lominadze D, Joshua IG, Schuschke DA. Increased erythrocyte aggregation in sponta-
neously hypertensive rats. American Journal of Hypertension. 1998;11:784-789
[37] Eidelman RS, Hennekens CH. Fibrinogen: A predictor of stroke and marker of athero-
sclerosis. European Heart Journal. 2003;24:499-500
[38] Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review 
of the literature. Annals of Internal Medicine. 1993;118:956-963
[39] Ross R. Mechanisms of disease - atherosclerosis - an inflammatory disease. The New 
England Journal of Medicine. 1999;340:115-126
[40] Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, 
Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, 
Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, 
de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, 
Jousilahti P, Pekkanen J, D'Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Pinango CL, 
Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, 
Diez-Ewald MP, Campos G, Fernandez V, Torres E, Coll E, Marchioli R, Valagussa F, 
Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, 
Rodriguez B, Yano K, Salonen JT, Nyyssonen K, Tuomainen TP, Hedblad B, Lind P, 
Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, 
Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Iso H, Rasi V, Palosuo T, 
Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, 
Schulte H, Assmann G, Cantin B, Lamarche B, Despres JP, Dagenais GR, Tunstall-Pedoe H, 
Woodward M, Ben Shlomo Y, Davey SG, Palmieri V, Yeh JL, Rudnicka A, Ridker P, 
Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, 
Kromhout D, Fibrinogen SC. Plasma fibrinogen level and the risk of major cardiovascu-
lar diseases and nonvascular mortality: An individual participant meta-analysis. JAMA. 
2005;294(14):1799-1809
[41] Lominadze D, Dean WL, Tyagi SC, Roberts AM. Mechanisms of fibrinogen-induced micro-
vascular dysfunction during cardiovascular disease. Acta Physiologica Scandinavica. 
2010;198:1-13
[42] Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neurovascular  damage 
and neuroinflammation in mouse models of Alzheimer's disease. The Journal of Exper-
imental Medicine. 2007;204:1999-2008
Traumatic Brain Injury - Pathobiology, Advanced Diagnostics and Acute Management116
[43] Hay JR, Johnson VE, Young AM, Smith DH, Stewart W. Blood-brain barrier disruption 
is an early event that may persist for many years after traumatic brain injury in humans. 
Journal of Neuropathology and Experimental Neurology. 2015;74:1147-1157
[44] Bayir A, Kalkan E, Kocak S, Ak A, Cander B, Bodur S. Fibrinolytic markers and neuro-
logic outcome in traumatic brain injury. Neurology India. 2006;54:363-365
[45] Nakae R, Takayama Y, Kuwamoto K, Naoe Y, Sato H, Yokota H. Time course of coagu-
lation and Fibrinolytic parameters in patients with traumatic brain injury. Journal of 
Neurotrauma. 2016;33:688-695
[46] Hayakawa M. Dynamics of fibrinogen in acute phases of trauma. Journal of Intensive 
Care. 2017;5:3
[47] Muradashvili N, Benton RL, Saatman KE, Tyagi SC, Lominadze D. Ablation of matrix 
metalloproteinase-9 gene decreases cerebrovascular permeability and fibrinogen depo-
sition post traumatic brain injury in mice. Metabolic Brain Disease. 2015;30:411-426
[48] Komarova Y, Malik AB. Regulation of endothelial permeability via paracellular and 
transcellular transport pathways. Annual Review of Physiology. 2010;72:463-493
[49] Nieswandt B, Kleinschnitz C, Stoll G. Ischaemic stroke: A thrombo-inflammatory dis-
ease? The Journal of Physiology. 2011;589:4115-4123
[50] Gonzales C, Pedrazzini T. Progenitor cell therapy for heart disease. Experimental Cell 
Research. 2009;315:3077-3085
[51] Savoia C, Schiffrin EL. Inflammation in hypertension. Current Opinion in Nephrology 
and Hypertension. 2006;15:152-158
[52] Wang TJ, Gona P, Larson MG, Levy D, Benjamin EJ, Tofler GH, Jacques PF, Meigs JB, 
Rifai N, Selhub J, Robins SJ, Newton-Cheh C, Vasan RS. Multiple biomarkers and the 
risk of incident hypertension. Hypertension. 2007;49:432-438
[53] Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nature Reviews. 
Immunology. 2011;11:98-107
[54] Pietropaolo M, Barinas-Mitchell E, Kuller LH. The heterogeneity of diabetes. Diabetes. 
2007;56:1189-1197
[55] Ross R. Atherosclerosis - an inflammatory disease. The New England Journal of Medicine. 
1999;340:115-126
[56] Abou-Raya A, Abou-Raya S. Inflammation: A pivotal link between autoimmune dis-
eases and atherosclerosis. Autoimmunity Reviews. 2006;5:331-337
[57] Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 
2008;454:445-454
[58] Broderick L, Tourangeau LM, Kavanaugh A, Wasserman SI. Biologic modulators in 
allergic and autoinflammatory diseases. Current Opinion in Allergy and Clinical Immu-
nology. 2011;11:355-360
Role of Fibrinogen in Vascular Cognitive Impairment in Traumatic Brain Injury
http://dx.doi.org/10.5772/intechopen.72610
117
[59] Savoia C, Sada L, Zezza L, Pucci L, Lauri FM, Befani A, Alonzo A, Volpe M. Vascular 
inflammation and endothelial dysfunction in experimental hypertension. International 
Journal of Hypertension. 2011;2011:281240-281247
[60] Curry F-RE, Noll T. Spotlight on microvascular permeability. Cardiovascular Research. 
2010;87:195-197
[61] Bazzoni G. Endothelial tight junctions: Permeable barriers of the vessel wall. Thrombosis 
& Haemostasis. 2006;95:36-42
[62] Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physio-
logical Reviews. 2006;86:279-367
[63] Michel CC, Curry FE. Microvascular permeability. Physiological Reviews. 1999;79:703-761
[64] Simionescu M, Popov D, Sima A. Endothelial transcytosis in health and disease. Cell and 
Tissue Research. 2009;335:27-40
[65] Clark TM, Hayes TK, Beyenbach KW. Dose-dependent effects of CRF-like diuretic 
peptide on transcellular and paracellular transport pathways. American Journal of 
Physiology. Renal Physiology. 1998;274:F834-F840
[66] Stan R-V, Marion K, Palade GE. PV-1 is a component of the fenestral and stomatal dia-
phragms in fenestrated endothelia. Proceedings of the National Academy of Sciences of 
the United States of America. 1999;96:13203-13207
[67] Tuma PL, Hubbard AL. Transcytosis: Crossing cellular barriers. Physiological Reviews. 
2003;83:871-932
[68] Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG. Brain 
plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in 
Alzheimer's disease brains. EMBO Reports. 2000;1:530-535
[69] Muradashvili N, Khundmiri SJ, Tyagi R, Gartung A, Dean WL, Lee M-J, Lominadze D. 
Sphingolipids affect fibrinogen-induced caveolar transcytosis and cerebrovascular per-
meability. American Journal of Physiology. Cell Physiology. 2014;307:C169-C179
[70] Ahn HJ, Zamolodchikov D, Cortes-Canteli M, Norris EH, Glickman JF, Strickland S. 
Alzheimer's disease peptide β-amyloid interacts with fibrinogen and induces its oligo-
merization. Proceedings of the National Academy of Sciences of the United States of 
America. 2010;107:21812-21817
[71] Schachtrup C, Ryu JK, Helmrick MJ, Vagena E, Galanakis DK, Degen JL, Margolis RU, 
Akassoglou K. Fibrinogen triggers astrocyte scar formation by promoting the avail-
ability of active TGF-β after vascular damage. The Journal of Neuroscience. 2010;30: 
5843-5854
[72] Cortes-Canteli M, Strickland S. Fibrinogen, a possible key player in Alzheimer’s disease. 
Journal of Thrombosis and Haemostasis. 2009;7:146-150
[73] Johnson VE, Stewart W, Smith DH. Traumatic brain injury and amyloid-[beta] pathol-
ogy: A link to Alzheimer's disease? Nature Reviews. Neuroscience. 2010;11:361-370
Traumatic Brain Injury - Pathobiology, Advanced Diagnostics and Acute Management118
[74] Muradashvili N, Tyagi R, Metreveli N, Tyagi SC, Lominadze D. Ablation of MMP9 gene 
ameliorates paracellular permeability and fibrinogen-amyloid beta complex forma-
tion during hyperhomocysteinemia. Journal of Cerebral Blood Flow and Metabolism. 
2014;34:1472-1482
[75] Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D, 
Bhuvanendran S, Fenz KM, Strickland S. Fibrinogen and β-amyloid association alters 
thrombosis and fibrinolysis: A possible contributing factor to Alzheimer's disease. 
Neuron. 2010;66:695-709
[76] Kalaria RN, Pax AB. Increased collagen content of cerebral microvessels in Alzheimer's 
disease. Brain Research. 1995;705:349-352
[77] Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Laurén J, Gimbel ZA, Strittmatter 
SM. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. 
The Journal of Neuroscience. 2010;30:6367-6374
[78] Chung E, Ji Y, Sun Y, Kascsak R, Kascsak R, Mehta P, Strittmatter S, Wisniewski T. Anti-
PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an 
Alzheimer's disease model mouse. BMC Neuroscience. 2010;11:130
[79] Fischer MB, Roeckl C, Parizek P, Schwarz HP, Aguzzi A. Binding of disease-associated 
prion protein to plasminogen. Nature. 2000;408:479-483
[80] Muradashvili N, Tyagi R, Tyagi N, Tyagi SC, Lominadze D. Cerebrovascular disorders 
caused by hyperfibrinogenemia. The Journal of Physiology. 2016;594:5941-5957
[81] Colombo E, Cordiglieri C, Melli G, Newcombe J, Krumbholz M, Parada L, Medico E, Hohlfeld R, 
Meinl E, Farina C. Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide 
production and neurodegeneration. The Journal of Experimental Medicine. 2012;209:521-535
[82] Bains M, Hall ED. Antioxidant therapies in traumatic brain and spinal cord injury. 
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2012;1822:675-684
[83] Schreibelt G, Kooij G, Reijerkerk A, van Doorn R, Gringhuis SI, van der Pol S, Weksler BB, 
Romero IA, Couraud P-O, Piontek J, Blasig IE, Dijkstra CD, Ronken E, de Vries HE. 
Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 
kinase, and PKB signaling. The FASEB Journal 2007;21:3666-3676
[84] Davalos D, Kyu Ryu J, Merlini M, Baeten KM, Le Moan N, Petersen MA, Deerinck TJ, 
Smirnoff DS, Bedard C, Hakozaki H, Gonias Murray S, Ling JB, Lassmann H, Degen JL, 
Ellisman MH, Akassoglou K. Fibrinogen-induced perivascular microglial  clustering is 
required for the development of axonal damage in neuroinflammation. Nature Commu-
nications. 2012;3:1227
[85] Hsiao TW, Swarup VP, Kuberan B, Tresco PA, Hlady V. Astrocytes specifically remove 
surface-adsorbed fibrinogen and locally express chondroitin sulfate proteoglycans. Acta 
Biomaterialia. 2013;9:7200-7208
[86] Cernich A, Kurtz S, Mordecai K, Ryan P. Cognitive rehabilitation in traumatic brain 
injury. Current Treatment Options in Neurology. 2010;12:412-423
Role of Fibrinogen in Vascular Cognitive Impairment in Traumatic Brain Injury
http://dx.doi.org/10.5772/intechopen.72610
119

